Key Regulatory Issues in Biosimilars
August 9, 2017

Axinn partner Chad Landmon participated in the FDLI sponsored webinar, "Key Regulatory Issues in Biosimilars." Joe Franklin, Associate Director for Policy, Therapeutic Biologics & Biosimilars Staff, Office of New Drugs, CDER, FDA and Christine Simmon, Senior Vice President of Policy and Strategic Alliances, Association of Accessible Medicines and Executive Director, Biosimilars Council, joined Chad to discuss significant issues impacting biosimilar development and marketing, including the Supreme Court’s recent decision on the "patent dance." John Manthei, Partner at Latham & Watkins LLP, moderated the discussion. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.